Identification

Name
Chloroprocaine
Accession Number
DB01161  (APRD00404)
Type
Small Molecule
Groups
Approved
Description

Chloroprocaine hydrochloride is a local anesthetic given by injection during surgical procedures and labor and delivery. Chloroprocaine, like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential.

Structure
Thumb
Synonyms
  • 2-Chloroprocaine
  • 4-amino-2-Chlorobenzoic acid 2-(diethylamino)ethyl ester
  • Chloroprocain
  • Chloroprocaine
  • Chloroprocainum
  • Chlorprocaine
  • Cloroprocaina
Product Ingredients
IngredientUNIICASInChI Key
Chloroprocaine hydrochlorideLT7Z1YW11H3858-89-7SZKQYDBPUCZLRX-UHFFFAOYSA-N
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
ClorotekalInjection, solution10 mg/mLIntrathecalSintetica Sa2017-10-04Not applicableUs
NesacaineInjection, solution10 mg/mLInfiltration; PerineuralFresenius Kabi2010-10-14Not applicableUs
NesacaineInjection, solution20 mg/mLInfiltration; PerineuralGeneral Injectables & Vaccines2013-01-30Not applicableUs
NesacaineInjection, solution20 mg/mLInfiltration; PerineuralFresenius Kabi2010-10-14Not applicableUs
NesacaineInjection, solution10 mg/mLInfiltration; PerineuralGeneral Injectables & Vaccines2011-10-03Not applicableUs
Nesacaine Ce 2% Inj 20mg/mlSolution20 mgEpidural; IntracaudalAstra Zeneca1984-12-312012-05-31Canada
Nesacaine Ce 3% Inj 30mg/mlSolution30 mgEpidural; IntracaudalAstra Zeneca1984-12-312005-08-02Canada
Nesacaine MPFInjection, solution30 mg/mLEpidural; Infiltration; Intracaudal; PerineuralFresenius Kabi2010-10-14Not applicableUs
Nesacaine MPFInjection, solution20 mg/mLEpidural; Infiltration; Intracaudal; PerineuralFresenius Kabi2010-10-14Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Chloroprocaine HydrochlorideInjection, solution20 mg/mLEpidural; InfiltrationHospira, Inc.1982-04-162016-10-13Us
Chloroprocaine HydrochlorideInjection, solution30 mg/mLEpidural; Infiltration; Intracaudal; PerineuralWest Ward Pharmaceutical1998-11-01Not applicableUs
Chloroprocaine HydrochlorideInjection, solution30 mg/mLEpidural; InfiltrationHospira, Inc.1982-04-162016-10-13Us
Chloroprocaine HydrochlorideInjection, solution20 mg/mLEpidural; Infiltration; Intracaudal; PerineuralWest Ward Pharmaceutical1998-11-01Not applicableUs
International/Other Brands
Nesacaine-CE (AstraZeneca) / Piocaine
Categories
UNII
5YVB0POT2H
CAS number
133-16-4
Weight
Average: 270.755
Monoisotopic: 270.113505569
Chemical Formula
C13H19ClN2O2
InChI Key
VDANGULDQQJODZ-UHFFFAOYSA-N
InChI
InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3
IUPAC Name
2-(diethylamino)ethyl 4-amino-2-chlorobenzoate
SMILES
CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1

Pharmacology

Indication

For the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia.

Structured Indications
Not Available
Pharmacodynamics

Chloroprocaine is an anesthetic agent indicated for production of local or regional anesthesia, particularly for oral surgery. Chloroprocaine (like cocaine) has the advantage of constricting blood vessels which reduces bleeding, unlike other local anesthetics like lidocaine. Chloroprocaine is an ester anesthetic.

Mechanism of action

Chloroprocaine acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited. The receptor site is thought to be located at the cytoplasmic (inner) portion of the sodium channel. It is hypothesized that Chloroprocaine binds or antagonizes the function of N-methyl-D-aspartate (NMDA) receptors as well as nicotinic acetylcholine receptors and the serotonin receptor-ion channel complex.

TargetActionsOrganism
ASodium channel protein type 10 subunit alpha
inhibitor
Human
UGlutamate receptor ionotropic, NMDA 3A
antagonist
Human
UNeuronal acetylcholine receptor subunit alpha-10
antagonist
Human
U5-hydroxytryptamine receptor 3A
antagonist
Human
USodium-dependent dopamine transporter
inhibitor
Human
Absorption

The rate of systemic absorption of local anesthetic drugs is dependent upon the total dose and concentration of drug administered, the route of administration, the vascularity of the administration site, and the presence or absence of epinephrine in the anesthetic injection.

Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Chloroprocaine is rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase.

Route of elimination

Chloroprocaine is rapidly metabolized in plasma by hydrolysis of the ester linkage by pseudocholinesterase. Urinary excretion is affected by urinary perfusion and factors affecting urinary pH.

Half life

21 +/- 2 seconds

Clearance
Not Available
Toxicity

In mice, the intravenous LD50 of chloroprocaine HCl is 97 mg/kg and the subcutaneous LD50 of chloroprocaine HCl is 950 mg/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Chloroprocaine Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Chloroprocaine.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Chloroprocaine.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Chloroprocaine.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Chloroprocaine.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Chloroprocaine.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Azaperone.Vet Approved
AzelastineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Barbital.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Chloroprocaine.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Chloroprocaine.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Brotizolam.Approved, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Chloroprocaine.Approved, Investigational
BuprenorphineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Chloroprocaine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Chloroprocaine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Chloroprocaine.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Chloroprocaine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carfentanil.Illicit, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Chloroprocaine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlormezanone.Approved, Withdrawn
ChlorphenamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Chloroprocaine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Chloroprocaine.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Chloroprocaine.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Chloroprocaine.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Chloroprocaine.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Chloroprocaine.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Chloroprocaine.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Chloroprocaine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Chloroprocaine.Approved
DesipramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Chloroprocaine.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Chloroprocaine.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Chloroprocaine.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Chloroprocaine.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Chloroprocaine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Chloroprocaine.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Chloroprocaine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ecgonine.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Chloroprocaine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Chloroprocaine.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Chloroprocaine.Approved
EthanolChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Chloroprocaine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl chloride.Experimental
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethylmorphine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Chloroprocaine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etoperidone.Approved
EtorphineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Chloroprocaine.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Flunitrazepam.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Chloroprocaine.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Chloroprocaine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Chloroprocaine.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluspirilene.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Chloroprocaine.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Fospropofol.Approved, Illicit
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Chloroprocaine.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Chloroprocaine.Approved, Illicit
GepironeThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Glutethimide.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Chloroprocaine.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Chloroprocaine.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Chloroprocaine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Hexobarbital.Approved
HyaluronidaseThe risk or severity of adverse effects can be increased when Hyaluronidase is combined with Chloroprocaine.Approved, Investigational
HydrocodoneChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Chloroprocaine.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Chloroprocaine.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Chloroprocaine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ketobemidone.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Chloroprocaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Chloroprocaine.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Chloroprocaine.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lithium.Approved
LofentanilThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Chloroprocaine.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Chloroprocaine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Chloroprocaine.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Chloroprocaine.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Melperone.Approved
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Chloroprocaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Chloroprocaine.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Chloroprocaine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Chloroprocaine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methadyl Acetate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Chloroprocaine.Approved
MethotrimeprazineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Chloroprocaine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Chloroprocaine.Approved
MetyrosineChloroprocaine may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Chloroprocaine.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved, Investigational
MirtazapineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Chloroprocaine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Chloroprocaine.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Chloroprocaine.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Chloroprocaine.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Chloroprocaine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Chloroprocaine.Approved
OpiumThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Opium.Approved, Illicit
OrphenadrineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Chloroprocaine.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxethazaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Chloroprocaine.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Chloroprocaine.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Chloroprocaine.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Chloroprocaine.Approved
ParaldehydeChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Chloroprocaine.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Chloroprocaine.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
PerazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Chloroprocaine.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Chloroprocaine.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Chloroprocaine.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Chloroprocaine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pipamperone.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pipotiazine.Approved
PiritramideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pomalidomide.Approved
PramipexoleChloroprocaine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Chloroprocaine.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Chloroprocaine.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Chloroprocaine.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Chloroprocaine.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Chloroprocaine.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Chloroprocaine.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Chloroprocaine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Chloroprocaine is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Chloroprocaine.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Chloroprocaine.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Chloroprocaine.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Chloroprocaine.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Chloroprocaine.Approved
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Chloroprocaine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Romifidine.Vet Approved
RopiniroleChloroprocaine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Chloroprocaine.Approved
RotigotineChloroprocaine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Chloroprocaine.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Chloroprocaine.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sertindole.Approved, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Chloroprocaine.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
StiripentolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Chloroprocaine.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Chloroprocaine.Approved
SultoprideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Sultopride.Experimental
SuvorexantChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tasimelteon.Approved
Technetium Tc-99m tilmanoceptChloroprocaine may decrease effectiveness of Technetium Tc-99m tilmanocept as a diagnostic agent.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Chloroprocaine.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tetrodotoxin.Investigational
ThalidomideChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Chloroprocaine.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Chloroprocaine.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Chloroprocaine.Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Chloroprocaine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Chloroprocaine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Chloroprocaine.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Chloroprocaine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Chloroprocaine.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trichloroethylene.Experimental
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Chloroprocaine.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Chloroprocaine.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Chloroprocaine.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Xylazine.Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Chloroprocaine.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Chloroprocaine.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zolazepam.Vet Approved
ZolpidemChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Chloroprocaine.Approved
ZotepineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Zotepine.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Chloroprocaine.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Marks, H.C. and Rubin, M.I.; US. Patent 2,460,139; January 25,1949; assigned to Wallace & Tiernan Products, Inc.

General References
Not Available
External Links
Human Metabolome Database
HMDB15292
KEGG Drug
D00732
KEGG Compound
C07877
PubChem Compound
8612
PubChem Substance
46508245
ChemSpider
8293
ChEBI
3636
ChEMBL
CHEMBL1179047
Therapeutic Targets Database
DAP000131
PharmGKB
PA448946
RxList
RxList Drug Page
Wikipedia
Chloroprocaine
ATC Codes
N01BA04 — Chloroprocaine
FDA label
Download (182 KB)
MSDS
Download (51.5 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedNot AvailableShort Duration Lower Limb Surgery Via Spinal Anaesthesia1
3Not Yet RecruitingTreatmentCesarean Section Complications / Pain1
3Not Yet RecruitingTreatmentUnplanned Caesarean Section1
3RecruitingOtherAxillary nerve block therapy1
4CompletedNot AvailableAnaesthesia therapy1
4CompletedTreatmentPain1
4Not Yet RecruitingNot AvailableAdverse Reaction to Spinal Anesthetic / Maternal Care for Cervical Incompetence1
4Not Yet RecruitingTreatmentCervical incompetence1
4Unknown StatusTreatmentPain Relief During Labour1
Not AvailableCompletedNot AvailableAmbulatory Surgical Procedures / Inguinal Hernias / Spinal Anaesthesia / Umbilical Hernias1
Not AvailableCompletedNot AvailableAnaesthesia therapy / Neonates and Infants Who Have Received Chloroprocaine for Epidural Anesthesia1
Not AvailableCompletedNot AvailableImpact of Anesthetic Choice on Costs1
Not AvailableCompletedTreatmentSpinal Anaesthesia1
Not AvailableRecruitingPreventionArterial Hypotension1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Dosage forms
FormRouteStrength
Injection, solutionEpidural; Infiltration20 mg/mL
Injection, solutionEpidural; Infiltration30 mg/mL
Injection, solutionIntrathecal10 mg/mL
Injection, solutionInfiltration; Perineural10 mg/mL
Injection, solutionInfiltration; Perineural20 mg/mL
SolutionEpidural; Intracaudal20 mg
SolutionEpidural; Intracaudal30 mg
Injection, solutionEpidural; Infiltration; Intracaudal; Perineural20 mg/mL
Injection, solutionEpidural; Infiltration; Intracaudal; Perineural30 mg/mL
Prices
Unit descriptionCostUnit
Nesacaine-mpf 3% vial1.34USD ml
Nesacaine-mpf 2% vial1.28USD ml
Nesacaine 2% vial0.74USD ml
Nesacaine 1% vial0.72USD ml
Chloroprocaine 3% vial0.33USD ml
Chloroprocaine 2% vial0.26USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)173-174Marks, H.C. and Rubin, M.I.; US. Patent 2,460,139; January 25,1949; assigned to Wallace & Tiernan Products, Inc.
water solubility0.665 mg/mLNot Available
logP2.86HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility1.3 mg/mLALOGPS
logP2.72ALOGPS
logP2.48ChemAxon
logS-2.3ALOGPS
pKa (Strongest Basic)8.96ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area55.56 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity75.1 m3·mol-1ChemAxon
Polarizability28.74 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9772
Blood Brain Barrier+0.954
Caco-2 permeable+0.6107
P-glycoprotein substrateSubstrate0.5855
P-glycoprotein inhibitor INon-inhibitor0.8563
P-glycoprotein inhibitor IINon-inhibitor0.9707
Renal organic cation transporterNon-inhibitor0.6843
CYP450 2C9 substrateNon-substrate0.8593
CYP450 2D6 substrateNon-substrate0.6718
CYP450 3A4 substrateNon-substrate0.5215
CYP450 1A2 substrateInhibitor0.7507
CYP450 2C9 inhibitorNon-inhibitor0.8687
CYP450 2D6 inhibitorInhibitor0.7746
CYP450 2C19 inhibitorNon-inhibitor0.8061
CYP450 3A4 inhibitorNon-inhibitor0.8334
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.6017
Ames testNon AMES toxic0.6613
CarcinogenicityNon-carcinogens0.6653
BiodegradationNot ready biodegradable0.9938
Rat acute toxicity2.7123 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8353
hERG inhibition (predictor II)Inhibitor0.5819
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-000i-9100000000-5a6841e384b0dfbd1238
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acid esters. These are ester derivatives of benzoic acid.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acid esters
Alternative Parents
2-halobenzoic acids and derivatives / Aminobenzoic acids and derivatives / Aniline and substituted anilines / Benzoyl derivatives / Chlorobenzenes / Aryl chlorides / Vinylogous halides / Trialkylamines / Amino acids and derivatives / Carboxylic acid esters
show 7 more
Substituents
Aminobenzoic acid or derivatives / Benzoate ester / 2-halobenzoic acid or derivatives / Halobenzoic acid or derivatives / Benzoyl / Aniline or substituted anilines / Chlorobenzene / Halobenzene / Aryl chloride / Aryl halide
show 19 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
monochlorobenzenes, benzoate ester (CHEBI:3636)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Voltage-gated sodium channel activity
Specific Function
Tetrodotoxin-resistant channel that mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference acro...
Gene Name
SCN10A
Uniprot ID
Q9Y5Y9
Uniprot Name
Sodium channel protein type 10 subunit alpha
Molecular Weight
220623.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Wong K, Strichartz GR, Raymond SA: On the mechanisms of potentiation of local anesthetics by bicarbonate buffer: drug structure-activity studies on isolated peripheral nerve. Anesth Analg. 1993 Jan;76(1):131-43. [PubMed:8418714]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein phosphatase 2a binding
Specific Function
NMDA receptor subtype of glutamate-gated ion channels with reduced single-channel conductance, low calcium permeability and low voltage-dependent sensitivity to magnesium. Mediated by glycine. May ...
Gene Name
GRIN3A
Uniprot ID
Q8TCU5
Uniprot Name
Glutamate receptor ionotropic, NMDA 3A
Molecular Weight
125464.07 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Receptor binding
Specific Function
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an i...
Gene Name
CHRNA10
Uniprot ID
Q9GZZ6
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-10
Molecular Weight
49704.295 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Voltage-gated potassium channel activity
Specific Function
This is one of the several different receptors for 5-hydroxytryptamine (serotonin), a biogenic hormone that functions as a neurotransmitter, a hormone, and a mitogen. This receptor is a ligand-gate...
Gene Name
HTR3A
Uniprot ID
P46098
Uniprot Name
5-hydroxytryptamine receptor 3A
Molecular Weight
55279.835 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Monoamine transmembrane transporter activity
Specific Function
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name
SLC6A3
Uniprot ID
Q01959
Uniprot Name
Sodium-dependent dopamine transporter
Molecular Weight
68494.255 Da
References
  1. Wilcox KM, Paul IA, Ordway GA, Woolverton WL: Role of the dopamine transporter and the sodium channel in the cocaine-like discriminative stimulus effects of local anesthetics in rats. Psychopharmacology (Berl). 2001 Sep;157(3):260-8. [PubMed:11605081]
  2. Mansbach RS, Jortani SA, Balster RL: Discriminative stimulus effects of esteratic local anesthetics in squirrel monkeys. Eur J Pharmacol. 1995 Feb 14;274(1-3):167-73. [PubMed:7768269]
  3. Wilcox KM, Paul IA, Woolverton WL: Comparison between dopamine transporter affinity and self-administration potency of local anesthetics in rhesus monkeys. Eur J Pharmacol. 1999 Feb 19;367(2-3):175-81. [PubMed:10078990]
  4. Wilcox KM, Rowlett JK, Paul IA, Ordway GA, Woolverton WL: On the relationship between the dopamine transporter and the reinforcing effects of local anesthetics in rhesus monkeys: practical and theoretical concerns. Psychopharmacology (Berl). 2000 Dec;153(1):139-47. [PubMed:11255924]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Kuhnert BR, Philipson EH, Pimental R, Kuhnert PM: A prolonged chloroprocaine epidural block in a postpartum patient with abnormal pseudocholinesterase. Anesthesiology. 1982 Jun;56(6):477-8. [PubMed:7081736]
  2. Tucker GT, Mather LE: Clinical pharmacokinetics of local anaesthetics. Clin Pharmacokinet. 1979 Jul-Aug;4(4):241-78. [PubMed:385208]
  3. Monedero P, Hess P: High epidural block with chloroprocaine in a parturient with low pseudocholinesterase activity. Can J Anaesth. 2001 Mar;48(3):318-9. [PubMed:11305839]
  4. Smith AR, Hur D, Resano F: Grand mal seizures after 2-chloroprocaine epidural anesthesia in a patient with plasma cholinesterase deficiency. Anesth Analg. 1987 Jul;66(7):677-8. [PubMed:3111302]
  5. Raj PP, Ohlweiler D, Hitt BA, Denson DD: Kinetics of local anesthetic esters and the effects of adjuvant drugs on 2-chloroprocaine hydrolysis. Anesthesiology. 1980 Oct;53(4):307-14. [PubMed:7425357]

Drug created on June 13, 2005 07:24 / Updated on October 02, 2017 04:54